DESIGN, PREPARATION, AND EVALUATION OF SELF-MICROEMULSIFYING DRUG DELIVERY SYSTEM OF BAMBUTEROL HYDROCHLORIDE by Saggar, Sachin et al.
Vol 11, Issue 12, 2018
Online - 2455-3891 
Print - 0974-2441
DESIGN, PREPARATION, AND EVALUATION OF SELF-MICROEMULSIFYING DRUG DELIVERY 
SYSTEM OF BAMBUTEROL HYDROCHLORIDE
SACHIN SAGGAR1*, ASHUTOSH UPADHAYAY2, MANISH GOSWAMI3
1,2Department of Pharmaceutical Sciences, MJRP College of Health Care & Allied Sciences, Mahatma Jyoti Rao Phoole University, Jaipur, 
Rajasthan, India. 3Department of Pharmaceutical Sciences, University Institute of Pharma Sciences, Chandigarh University, Mohali, 
Punjab, India. Email: sachinsaggar@yahoo.com
Received: 01 June 2018, Revised and Accepted: 09 August 2018
ABSTRACT
Objective: The self-micro-emulsifying drug delivery system (SMEDDS) of bambuterol hydrochloride was designed, prepared, and evaluated to 
overcome the problem of poor bioavailability.
Methods: The designing of the formulation included the selection of oil phase, surfactant, and cosolvent/cosurfactant based on the saturated solubility 
studies. Psuedoternary phase diagram was constructed using aqueous titration method, to identify the self-emulsifying region. Different ratios of the 
selected surfactant and cosolvent/cosurfactant (Smix) were also studied and used to construct the ternary phase diagram. The prepared formulations 
of the SMEDDS were evaluated for drug content, morphology, globule size, robustness to dilution, emulsification time, optical clarity, and stability.
Results: The formulation containing 10 mg bambuterol hydrochloride, triacetin (12.50% w/w), Tween 80 (43.75% w/w), and ethanol (43.75% w/w) 
was concluded to be optimized. The optimized SMEDDS not only showed optimum globule size, zeta potential, and drug content but was also found 
to be robust to dilution, formed emulsion spontaneously, and was stable. The optimized SMEDDS showed increased permeability of the drug across 
the intestinal membrane in ex vivo studies.
Conclusion: The results suggest that bambuterol hydrochloride can be formulated as self-microemulsifying drug delivery system, and further, 
SMEDDS can be used to improve the oral bioavailability of bambuterol hydrochloride.
Keywords: Self-microemulsifying drug delivery system, Bambuterol hydrochloride, Phase diagram, Zetasizer, Everted gut technique.
INTRODUCTION
Self-emulsifying drug delivery system (SEDDS) refers to a formulation 
comprising an isotropic mixture of natural and synthetic oils 
with hydrophilic or lipophilic surfactants and cosolvent(s) which 
spontaneously emulsifies when exposed to the gastrointestinal fluid to 
form oil-in-water emulsion [1-4]. The emulsion so produced is a clear 
dispersion in which the particle size of the dispersed phase ranges from 
nanometers to several microns. In case of microemulsions, the average 
diameter of the dispersed phase is in size range of 10–100 nm, whereas 
in nanoemulsions, droplet size is in the range of 50–1000 nm (preferably 
from 100 to 500 nm). The main difference between microemulsions 
and nanoemulsions is regarding their physical stability, appearance, 
and microstructure [5]. On peroral administration, SEDDS form fine 
emulsions (or microemulsions) in the gastrointestinal tract (GIT) with 
mild agitation provided by gastric mobility [6,7]. The difference between 
a SEDDS and self-microemulsifying drug delivery system (SMEDDS) is 
that the former when diluted results in a droplet size between 100 and 
300 nm and the latter result in a droplet size of <50 nm [8].
SEDDS can overcome the problems associated with various drugs falling 
in various Biopharmaceutical Classification System (BCS) classes, and 
in case of BCS Class III drugs, SEDDS can overcome the problem of 
enzymatic degradation, gut wall efflux, and bioavailability [9].
The presence of the lipids in the formulation leads to the delay in the 
gastric emptying, resulting in the increase in the gastric residence time. 
Therefore, the drug remains for prolong time in the GIT which enables 
better dissolution of the drug at the absorption site and therefore 
increases the absorption [10]. In the presence of the increased bile 
salt concentration, the breakdown product of the lipids digestion is 
incorporated into series of colloidal structure such as micelles which 
increases the solubilization capacity of the small intestine for the 
lipid-digested product and the drug [10,11].
A number of lipids have shown the ability to alter the permeability 
of the gut wall and increase the permeability of the intestine [12]. 
Lipids may enhance the extent of lymphatic transport and increase 
the bioavailability directly or indirectly by reduction in first-pass 
metabolism. Certain lipids and surfactants have shown the tendency 
to reduce the activity of the efflux transporters in the GI wall, thereby 
increasing the amount of drug absorbed. This mechanism may also 
lead to reduced intraenterocyte metabolism since there is an interplay 
between P-gp and CYP3A4. Cremophor EL, Labrasol, Polysorbate 80, 
and Polysorbate 20 have shown P-gp inhibitory activity [13].
Bambuterol hydrochloride is 5-[(1RS)-2-[(1,1-dimethylethyl)
amino]-1-hydroxyethyl]-1,3-phenylene bis(dimethylcarbamate) 
hydrochloride  [14].  Bambuterol  is  a  long-acting  β-2  adrenoceptor 
agonist used in the treatment of asthma. It is a prodrug of terbutaline. 
Bambuterol causes smooth muscle relaxation, resulting in dilation of 
bronchial passages. It is freely soluble in water [14]. On average, 20% of 
an oral dose is absorbed. Protein binding of bambuterol is low, 40–50% 
at therapeutic concentrations. The terminal half-life of bambuterol 
after an oral dose is 9–17 h. Bambuterol is metabolized in the liver, and 
terbutaline is formed by both hydrolysis and oxidation. After absorption 
from the gut, about two-third of absorbed bambuterol survives first-pass 
metabolism, and rest third is metabolized to intermediary metabolites 
which are still prodrugs of terbutaline. Terbutaline has a bioavailability 
of about 10% of administered dose [15,16]. Renal clearance after oral 
administration is around 1250 mL/min.
© 2018 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2018.v11i12.27890
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Bambuterol is available as 10 mg and 20 mg tablet for oral 
administration. The dosage of bambuterol is 10 mg per day, but it may 
also be administered up to 20 mg per day. Bambuterol is also available 
in the liquid dosage form in the strength of 1 mg/mL and 2 mg/mL.
In this study, SMEDDS of bambuterol has been prepared by 
ultrasonication method. The main purpose behind choosing SMEDDS 
formulation for bambuterol was that lipid-based formulation enhances 
the permeability of the drug, thereby increasing the bioavailability of 
the drug. Moreover, the side effects such as tremors associated with β-2 
agonists are dose dependent. Hence, the aim of the present study was to 
develop the SMEDDS of bambuterol to enhance its bioavailability which 
may lead to the reduction in dose and side effect of the drug.
MATERIALS AND METHODS
Materials
Bambuterol hydrochloride was purchased from Yarrow Chem Products, 
Mumbai. Tween 80 was gifted by Eden drugs Pvt. Ltd., Amritsar. 
Triacetin was gifted by Alkon Lab., Amritsar. Distilled water, hydrochloric 
acid (Ramkem LR grade), potassium chloride (Qualigens AR grade), 
potassium dihydrogen phosphate (CDH LR), disodium hydrogen 
phosphate, sodium chloride (S.D. Fine chem., extra pure), and ethanol 
(Changshu Hongsheng Fine Chemical, AR) were used in the study.
Methods
Solubility of bambuterol in oil, surfactant, and cosolvent
The solubility of the bambuterol in various oils (isopropyl myristate, 
triacetin, oleic acid, ethyl oleate, and labrafil 1944), surfactant 
(Tween 80, labrasol, and cremophor EL), and cosolvent/cosurfactant 
(propylene glycol [PG], polyethylene glycol 400, ethanol, and transcutol) 
was determined by dissolving excess amount of drug in 3 mL of 
each of selected oil, surfactant, and cosolvent/cosurfactant in a 5 mL 
stoppered vial. The excess amount of drug was mixed using a vortex 
mixer. The vials were then kept at 37±1°C in an isothermal shaker 
for 72 h to get to equilibrium. The equilibrated samples were then 
centrifuged at 3000 rpm for 15 min. The supernatant of the centrifuged 
samples was carefully separated/removed with the help of syringe 
and needle without disturbing the precipitated portion of the samples. 
The concentration of the drug in each of the samples was estimated 
by diluting the samples with isopropyl alcohol and measuring the 
absorbance at 265 nm using (UV 1800 Shimadzu, Japan) ultraviolet 
spectrophotometer [17-21].
Construction of pseudoternary phase diagram
Pseudoternary phase diagrams were constructed to identify the regions 
such as o/w microemulsion or nanoemulsion, coarse emulsion, and gel/
viscous region by diluting specific oil/surfactant/cosolvent/cosurfactant 
mixture with water. The phase diagram is helpful to determine the 
appropriate concentration range and ratios of the components that can 
result in micro or nanoemulsion. The phase diagrams were constructed 
using aqueous titration method or spontaneous emulsification method. 
First of all, various ratios of surfactant and cosolvent/cosurfactant 
were prepared by mixing selected surfactant and selected cosolvent/
cosurfactant in various proportions such as 1:1, 1:2, and 1:3 w/w. The 
mixture of surfactant and cosolvent/cosurfactant is termed as Smix. 
Thereafter, different types of Smix were mixed with selected oil in ratios 
of 9:1, 8:2, 7:3, 6:4, 5:5, 4:6, 3:7, 2:8, and 1:9 w/w in a glass vial at room 
temperature by vortexing for at least 5 min. Each ratio of Smix mixed 
with oil was then titrated with distilled water in increments of 25 µL 
of water using a micropipette, and the sample was vigorously mixed 
by vortexing for at least 2 min and then kept at room temperature for 
10 min to reach equilibrium before next addition of water. The process 
was repeated either until the sample turned turbid or until 90.90% w/w 
addition of water. The phase behavior of each ternary phase system was 
minutely observed during the titration. The percentage composition of 
each component in the ternary system was determined, and the results 
were plotted on the triangular coordinates to construct the phase 
diagram [22,23].
The same process was repeated with all the other ratios of surfactant 
and cosurfactant.
Pseudoternary phase diagram was constructed using Triplot software.
Preparation of SMEDDS
The amount of the oil, surfactant, and cosolvent/cosurfactant to be 
taken was decided on the basis of microemulsification region in the 
ternary phase diagram. Bambuterol hydrochloride was accurately 
weighed and dissolved in the required quantity of oil and Smix 
(surfactant and co-solvent/co-surfactant), taken in a screw-capped 
glass vial by sonicating at 37°C for maximum up to 30 min. Thirteen 
formulations each containing different concentrations of oil, surfactant, 
and cosurfactant were prepared. Each formulation contained 10 mg of 
bambuterol hydrochloride.
Physiochemical characterization/evaluation of SMEDDS [17-21,24]
Emulsification time
Emulsification time is the time taken by the preconcentrate to form 
a homogeneous mixture on dilution. It was monitored by visual 
observation. In this method, 1 g of each preconcentrate containing 
bambuterol hydrochloride equivalent to 10 mg was diluted to 100 mL 
distilled water with the help of magnetic stirrer (100 rpm at 37°C), and 
time taken to form microemulsion was observed. The studies were 
done in triplicate [20,24,25].
Globule size determination
1 g of each preconcentrate containing bambuterol hydrochloride 
equivalent to 10 mg was diluted with 100 mL of distilled water in a 
volumetric flask and was sonicated at 37°C for 10 min. The sample was 
allowed to equilibrate for 15 min and the droplet size of the resultant 
microemulsion was determined by photon correlation spectroscopy 
that analyzes the fluctuation in the light scattering due to the Brownian 
motion of droplets as a function of time using Zetasizer Nano Series 
(Beckman Coulter-Delsa Nano). The same process was repeated with 
0.1 N hydrochloric acid [17-20,24].
Zeta potential
The emulsion stability is directly related to the magnitude of the 
surface charge. The zeta potential of the diluted SMEDDS formulation 
used for globule size measurement was measured using a Zetasizer 
(Beckman Coulter-Delsa Nano). The SMEDDS was diluted with distilled 
water [17-20,24].
Visual assessment and robustness to dilution
Robustness to dilution was studied by diluting 1 g of the preconcentrate 
containing bambuterol hydrochloride equivalent to 10 mg with 100 mL 
distilled water, 0.1 N hydrochloric acid, and pH 6.8 buffer with the 
help of magnetic stirrer (100 rpm at 37°C) and the resultant dilution 
was kept for 24 h at room temperature for observation. The SMEDDS 
was graded from Grade I to Grade IV on the basis of their physical 
appearance based on visual assessment of the microemulsion formed 
on dilution. The emulsion formed on dilution may vary from clear to 
milky in appearance. The studies were done in triplicate [18-20,25,26].
Percentage transmission/optical clarity
1 g of each preconcentrate containing bambuterol hydrochloride 
equivalent to 10 mg was diluted with 100 mL of distilled water in a 
beaker with help of magnetic stirrer (100 rpm at 37°C). Percentage 
transmission of each dispersion was measured at 400 nm using UV 
spectrophotometer at 0 h, 12 h, and 24 h. The studies were done in 
triplicate [24,26].
Cloud point test
1 g of the preconcentrate was diluted to 250 mL with distilled water, the 
resultant dilution was placed on a water bath, and the temperature of 
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the water bath was gradually increased from 35°C to 100°C. The cloud 
point was measured at the temperature at which there was sudden 
appearance of cloudiness. The studies were done in triplicate [18,25,26].
Viscosity
20 g of each preconcentrate was weighed and transferred to a beaker, 
and viscosity of the formulation was determined with the help of 
Fungilab-viscolead-Pro viscometer, spindle-PC at 12, 6, and 2 rpm for 
5 min. Viscosity measurement was done in triplicate [18].
Refractive index
Refractive index of preconcentrate loaded with drug and preconcentrate 
without drug was determined using Abbe’s type refractometer. 
Refractive index measurement was done in triplicate [20].
Drug content
Bambuterol hydrochloride was extracted from the SMEDDS in pH 6.8 
buffer using ultrasonication technique. The solutions of SMEDDS were 
sonicated for 10 min at 37°C and then allowed to equilibrate for another 
10 min. Thereafter, the solutions were filtered through Whatman 
filter paper. The filtrates were analyzed for content of bambuterol 
hydrochloride using UV spectrophotometric technique at 264 nm. Drug 
content estimation studies were done in triplicate [17,19,24].
Stability studies
Stability of the formulations (shelf life) as a function of time and storage 
temperature was evaluated by visual inspection of the self-emulsifying 
drug delivery system at different time periods up to 6 months. The 
parameters evaluated for stability studies by visual inspection included 
phase separation, precipitation of the drug, or any other excipients. 
Each preconcentrate containing 10 mg of the drug, bambuterol 
hydrochloride, was diluted with distilled water to form 5 g formulation. 
The dilution was done as per the ratios of all the three components 
(oil, Smix, and water) obtained from the phase diagram. Similarly, 
preconcentrate without drug was also diluted with distilled water to 
form 5 g formulation, and this formulation was to act as blank and was 
useful in comparison.
5 g of each formulation containing bambuterol hydrochloride 
equivalent to 10 mg was stored in a well-closed container at room 
conditions for 6 months. Similarly, 5 g of each formulation without 
bambuterol hydrochloride was also stored in a well-closed container 
at room conditions for 6 months. The formulations were periodically 
checked for any precipitation/sedimentation, phase separation, and 
any other changes.
In another stability study, 10 mg of the drug bambuterol hydrochloride 
was dissolved in each preconcentrate and was stored in a well-closed 
container at room conditions for 6 months. Similarly, preconcentrate 
without bambuterol hydrochloride was also stored in a well-closed 
container at room conditions for 6 months. The formulations were 
periodically checked for any precipitation/sedimentation, phase 
separation, and any other changes.
These studies were also useful in comparing the stability of the SMEDDS 
and the microemulsion, up to 6 months [20].
Thermodynamic stability studies
Heating and cooling cycle/stability testing
Each preconcentrate containing 10 mg of the drug, bambuterol 
hydrochloride, was diluted with distilled water to form 5 g formulation, 
as mentioned above. 5 g of each formulation was then subjected to 
six cycles between refrigerated temperatures 4°C and 25±1°C (since 
formulation contains ethanol which has a flash point below 45°C, hence 
the stability testing was performed at temperatures around 25°C) with 
storage at each temperature for not <48 h. The formulations which 
were stable at these temperatures were subjected to centrifuge test.
Centrifuge test
Passed formulations were centrifuged at 3500 rpm for 30 min using a 
digital centrifuge [18,20,25].
Comparative ex vivo intestinal permeability studies
The everted gut technique was employed for the ex vivo intestinal 
permeability studies. Fresh intestine of chicken was taken, and from 
the intestine, 5–6 cm long portion of ileum was removed and washed 
thoroughly and then everted immediately. The removed portion of 
ileum was checked for leaks by filling it with 0.9% w/v normal saline 
solution. The ileum was then suspended/hanged in a beaker filled 
with Krebs-Ringer phosphate buffer (pH 7.2–7.4) in “U-shaped” 
manner in such a way that both the ends of the ileum were available 
for withdrawing and replenishing the sample. Thereafter, bambuterol 
hydrochloride dissolved in preconcentrate was introduced in the beaker 
with stirring. The system was maintained at 37±1°C and stirred at 
50 rpm with the help of magnetic stirrer. The ileum was filled with 5 mL 
of Krebs-Ringer phosphate buffer (pH 7.2–7.4). 2 mL of sample was 
withdrawn from the ileum with the help of syringe at predetermined 
intervals, and the amount withdrawn from the ileum was immediately 
replenished to maintain sink condition. Samples were withdrawn up to 
2 h. The drug content in each of the samples was determined by UV 
Spectrophotometric method [24,27].
The whole process was repeated by replacing SMEDDS formulation 
with bambuterol hydrochloride dissolved in distilled water. The 
amount of drug permeating across the membrane/intestine for the 
drug in solution and the drug in SMEDDS was compared.
The intestinal permeability is one of the major factors that govern the 
rate and extent of absorption [28].
Statistical analysis
Origin 9.0 software was used for statistical analysis. Where the studies 
have been done in triplicate, the data represent the mean ± standard 
deviation. The statistical analysis was performed using student’s t-test. 




To develop a good self-emulsifying drug delivery system, the drug 
should have a sufficient/good solubility in the oil, surfactant, and 
cosolvent/cosurfactant system. Bambuterol showed maximum 
solubility in triacetin (635.12±4.88 µg/mL) (Fig. 1) compared to 
other oils evaluated for solubility, and similarly, bambuterol showed 
maximum solubility in Tween 80 (14.05±0.697 mg/mL) (Fig. 2) 
compared to other surfactant and in ethanol (26.538±3.135 mg/
mL) (Fig. 3) (p<0.05, t-test) when compared to other cosolvents/
cosurfactant. Bambuterol hydrochloride also showed sufficient 
Fig. 1: Solubility chart of bambuterol hydrochloride in different 
oils (mean±SD; n=3)
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solubility in PG (9.464±0.260 mg/mL); therefore, two systems one 
constituting triacetin, Tween 80, and ethanol and another constituting 
triacetin, Tween 80, and PG were selected as oil, surfactant, and 
cosolvent/cosurfactant, respectively, for further studies.
Construction of pseudoternary phase diagram
The phase diagram was constructed using aqueous titration 
method or spontaneous emulsification method to identify the self-
microemulsifying region. First of all, Smix was prepared by mixing 
Tween 80 and ethanol in following proportions 1:1, 2:1, 3:1, and 
1:2 w/w, respectively. Thereafter, Smix was added to triacetin in ratios 
of 9:1, 8:2, 7:3, 6:4, 5:5, 4:6, 3:7, 2:8, and 1:9 w/w in a glass vial at room 
temperature, and the resultant mixture was vortexing for at least 5 min. 
The Smix-triacetin mixture was then titrated with distilled water in 
increments of 25 µL of water using a micropipette, and each sample 
was vigorously mixed by vortexing for at least 2 min and then kept at 
room temperature for 10 min to reach equilibrium before next addition 
of water. The process was repeated either until each sample turned 
turbid or till 90.90% w/w addition of water. The phase behavior of each 
ternary phase system was minutely observed during the titration. The 
percentage composition of triacetin, Tween 80, ethanol, and water in 
the ternary system was determined, and the results were plotted on 
the triangular coordinates to construct the phase diagram. From the 
phase diagram, the percentage composition w/w of triacetin, Tween 
80, ethanol, and water that will form SMEDDS was determined. Smix 
prepared by mixing Tween 80 and ethanol in ratio 1:1, 2:1, and 1:2 was 
selected for further studies, and Smix ratio 3:1 was rejected because 
the microemulsion region decreased with increase in the proportion 
of Tween 80 and was therefore not conducive for further studies 
(Figs. 4–6).
The same process was repeated with triacetin, Tween 80, and PG. Smix 
was prepared by mixing Tween 80 and PG in following proportions 1:1, 
2:1, and 1:2 w/w, respectively. Smix prepared by mixing Tween 80 and 
PG in ratio 1:1 and 1:2 was selected for further studies and Smix ratio 
2:1 was rejected because the microemulsion region decreased with the 
increase of Tween 80 (Figs. 7 and 8).
Various formulations were prepared by mixing triacetin, Tween 80, and 
ethanol in various percentage w/w proportions. These formulations 
were further evaluated for various parameters including globule size 
and phase separation on storage. The same procedure was also adopted Fig. 2: Solubility chart of bambuterol hydrochloride in different 
surfactants  (mean±SD; n=3)
Fig. 3: Solubility chart of bambuterol hydrochloride in different 
cosolvents/cosurfactants (mean±SD; n=3)
Fig. 4: Pseudoternary phase diagram of triacetin, Smix (Tween 
80:ethanol [1:1]), and water
Fig. 5: Pseudoternary phase diagram of triacetin, Smix (Tween 80: 
ethanol [2:1]), and water
Fig. 6: Pseudoternary phase diagram of triacetin, Smix (Tween 80: 
ethanol [1:2]), and water
393
Asian J Pharm Clin Res, Vol 11, Issue 12, 2018, 389-398
 Saggar et al. 
for preparation and evaluation of formulations containing triacetin, 
Tween 80, and PG system.
On the basis of the phase diagram studies, 13 formulations/
compositions (Table 1) were selected for further studies.
Preparation of SMEDDS
Thirteen formulations (F1-F13) with different concentrations of oil, 
surfactant, and co-surfactant each containing 10 mg of bambuterol 
hydrochloride were prepared by ultrasonication method and 
evaluated.
Physiochemical characterization/evaluation of SMEDDS
Emulsification time
The efficiency of the emulsion can be determined by the emulsification 
time/rate of emulsification. The SMEDDS should disperse spontaneously 
and completely on dilution with distilled water under mild agitation. 
The emulsification time for all the 13 formulations was found to be 
≤10 s (Table 2). This indicates that all the 13 SMEDDS formulations of 
bambuterol disperse spontaneously and completely on dilution. This 
can be attributed to the presence of surfactant systems which reduces 
interfacial tension between oil and water phases and enables rapid 
dispersion to form o/w emulsion. The studies were done in triplicate.
Globule size determination, polydispersity index (PDI), and zeta 
potential
The droplet size of the liquid SMEDDS is the most crucial factor in 
SMEDDS performance as it determines the rate and extent of drug 
release and absorption. Smaller droplet size will present a large area for 
drug absorption and hence increase bioavailability [3,29]. Increase in 
concentration of oil leads to an increase in globule size. The reduction 
in droplet size can be attributed to the stabilization of oil droplets due to 
the localization of surfactant monolayers at the oil-water interface [30]. 
The globule size of the SMEDDS in distilled water ranged from 14.5 nm 
to 1241.3 nm. The lowest globule size was observed in SMEDDS F1, F2, 
F4, F5, F6, F7, F8, F10, and F11. The SMEDDS F4 and F5 also showed 
goods results, but since they contained a relatively high concentration of 
surfactant which can cause irritation of mucosa, therefore SMEDDS F1, 
F2, F6, F7, F10, and F11 were preferred over F4 and F5 (Table 3). In case 
of formulation F1–F9, it was observed that increase in ratio of oil resulted 
in proportionate increase in the droplet size. The presence of surfactants 
in the SMEDDS causes interfacial film to stabilize and condense, while 
cosurfactant causes the film to expand; thus, relative proportion of 
surfactant and co-surfactant has varied effects on the globule size [19].
Further, the globule size of SMEDDS in 0.1 N hydrochloric acid was also 
determined and it was found to be in the range of 14–89.1 nm. This 
shows that the SMEDDS will produce droplet in microemulsion range 
in the gastric pH (Table 4).
The PDI of all the SMEDDSs ranged from 0.119 to 0.567 (Table 3), and 
the lowest PDI was reported for formulation F10. The PDI below 0.3 
indicates good uniformity in the globule size distribution after dilution 
with water [31,32]. PDI of SMEDDS F1 was found to be 0.312 which 
indicates uniform globule distribution (Table 3).
Zeta potential of the SMEDDS in distilled water was found to be in the 
range of +26.7 mV to –8.44 mV. In general, formulations having zeta 
Fig. 7: Pseudoternary phase diagram of triacetin, Smix (Tween 80: 
PG [1:1]), and water
Fig. 8: Pseudoternary phase diagram of triacetin, Smix (Tween 80: 
PG [1:2]), and water
Table 1: Selected Composition at different % w/w of oil, surfactant and co-surfactant for bambuterol SMEDDS
Composition Code Smix Smix Ratio Pre-concentrate Oil:Smix Precon.:water (for stability studies)
Oil (parts) Tween 80 (parts) Ethanol (parts)
F 1 1:1 12.50 43.75 43.75 1:7 1:1.5
F 2 Smix  1 1:1 13.80 43.10 43.10 1:6.25 1:0.724
F 3 1:1 15.38 42.31 42.31 1:5.5 1:0.538
F 4 2:1 12.50 58.33 29.17 1:7 1:1.5
F 5 Smix  2 2:1 13.80 57.47 28.73 1:6.25 1:0.724
F 6 2:1 15.38 56.41 28.20 1:5.5 1:0.538
F 7 1:2 12.50 29.17 58.33 1:7 1:1.5
F 8 Smix  3 1:2 13.80 28.73 57.47 1:6.25 1:0.724
F 9 1:2 15.38 28.20 56.41 1:5.5 1:0.538
F 10 Smix  4 1:2 9.09 30.30 60.60 1:10 1:0.818
F 11 1:2 14.30 28.57 57.13 1:6 1:0.428
F 12 Smix  5 1:1 9.09 45.45 45.45 1:10 1:0.818
F 13 1:1 14.30 42.85 42.85 1:6 1:0.428
Precon: pre-concentrate; P.G.: propylene glycol
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potential value of ±30 mV are considered to be stable. Higher the zeta 
potential, greater will be the energy barrier to coalescence between 
oil globules and so higher will be the stability of obtained emulsion 
[25]. SMEDDS F1, F2, F6, F7, F10, and F11 complied with zeta potential 
requirement for stability (Table 3 and Figs. 9 and 10).
Visual assessment and robustness to dilution
All the SMEDDSs on dilution of up to 100 times with distilled water, 0.1 
N hydrochloric acid, and pH 6.8 buffer and on storage up to 24 h did not 
show any sign of phase separation, turbidity, and drug precipitation though 
SMEDDS F7, F8, and F9 were transparent to slightly bluish only after 24 h 
(Table 5). F7–F9 can still be categorized as Grade I emulsion, but since they 
had shown a tendency to turn slightly bluish and as they contained a high 
amount of ethanol, therefore, other formulations were preferred over F7–F9. 
The clarity of the dispersion may be due to the presence of higher percentage 
of surfactant as compared to oil. The studies were done in triplicate.
The SMEDDS was graded as Grades I–IV on basis of visual assessment. 
Table 6 specifies the grading of the emulsion depending on their physical 
appearance based on visual assessment of the microemulsion formed on 
dilution. Since all the SMEDDS formed clear emulsion spontaneously and 
were also robust to dilution, the SMEDDS was categorized as Grade I.
Cloud point test
Cloud point is an important parameter to assess the stability of the 
formulations. The cloud point is the temperature above which there 
is sudden appearance of cloudiness, and this cloudiness is due to the 
precipitation or phase separation of the drug or any other excipient 
from the microemulsion formed from the SMEDDS. Higher cloud point 
indicates greater stability of the SMEDDS during shelf life. In general, 
the cloud point of the formulations should be above body temperature 
(37°C) [26]. All the SMEDDSs (F1–F13) when subjected to cloud point 
test did not show any sign of cloudiness even at high temperatures. 
Hence, it can be inferred that the formulations will be stable at 
physiological pH without the risk of phase separation (Table 7). The 
studies were done in triplicate.
Percentage transmission/optical clarity
Optical clarity was determined by measuring the percentage 
transmission of the SMEDDS diluted with distilled water at 400 nm. 
Table 2: Emulsification time of different bambuterol SMEDDS














Table 3: Globule size, zeta potential, and PDI of bambuterol 






F1 24.1 1.65 0.314
F2 39.8 −8.44 0.359
F3 1241.3 −0.75 0.521
F4 37.9 1.41 0.237
F5 14.5 0.30 0.220
F6 751.5 6.96 0.323
F7 22.1 0.22 0.32
F8 84.4 26.7 0.567
F9 1059.3 4.97 0.455
F10 24.4 −0.17 0.119
F11 20.7 0.09 0.389
F12 599.4 2.63 0.286
F13 539.3 −0.52 0.250
PDI: Polydispersity index
Table 4: Globule size and poly dispersity index of bambuterol 
SMEDDS in 0.1 N HCl















Fig. 9: Zetasizer report of self-microemulsifying drug delivery 
system F1 in distilled water
Fig. 10: Zetasizer report of self-microemulsifying drug delivery 
system F10 in distilled water
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Optical clarity is also the measure of droplet stability, and any significant 
change in optical clarity on storage indicates droplet instability. The 
results of the optical clarity test are reported in Table 8 (p<0.05, t-test). 
It was found that there is negligible change in transmission of light over 
24 h for all the SMEDDSs. The result of the optical clarity test, when 
read along with results of robustness to dilution test, indicates that all 
the SMEDDSs are not only stable to dilution, but the droplets formed 
on dilution are also stable for 24 h. The measurements were done in 
triplicate.
Refractive index
The results of the refractive index of the preconcentrate loaded with 
drug and preconcentrate without drug for all the 13 SMEDDSs show 
that there was very negligible change in the refractive index of the 
system (Table 9). Therefore, it can be concluded that SMEDDS is not 
only thermodynamically stable but also chemically stable, and there 
was no chemical reaction between excipients and the drug.
Viscosity
The viscosity of the SMEDDS can affect the rate of absorption. The 
viscosity of the SMEDDS containing Tween 80 and PG as Smix, 
i.e., F10–13 was more than those SMEDDS containing Tween 80 
and ethanol as Smix, i.e., F1–9. Further, the viscosity of the SMEDDS 
increased with an increase in content of Tween 80, and the viscosity of 
formulation containing Smix in ratio of 2:1 was more than the viscosity 
of formulation containing Smix in ratio 1:1 which was greater than 
formulation containing Smix in ratio 1:2, i.e., viscosity of F4-6 > F1–3 
> F6–9 (Table 10). From the viscosity studies, it was observed that the 
nature and concentration of the surfactant and cosurfactant affect the 
Table 5: Result of robustness to dilution of bambuterol SMEDDS
Preconcentrate Distilled water 0.1 N HCl pH 6.8 buffer
0 h 12 h 24 h 0 h 12 h 24 h 0 h 12 h 24 h
F1 T T T T T T T T T
F2 T T T T T T T T T
F3 T T T T T T T T T
F4 T T T T T T T T T
F5 T T T T T T T T T
F6 T T T T T T T T T
F7 T T T T T T T T T/slight bluish
F8 T T T T T T T T T/slight bluish
F9 T T T T T T T T T/slight bluish
F10 T T T T T T T T T
F11 T T T T T T T T T
F12 T T T T T T T T T/slight bluish
F13 T T T T T T T T T/slight bluish
T: Transparent, HCl: Hydrochloric acid, SMEDDS: Self-microemulsifying drug delivery system
Table 6: Grading of bambuterol SMEDDS based on the visual 
assessment
Appearance Grade
Clear to slightly bluish Emulsion Grade I
Bluish emulsion Grade II
Bluish to slightly white emulsion Grade III
White or milky emulsion Grade IV
SMEDDS: Self-microemulsifying drug delivery system
Table 7: Result of cloud point test of bambuterol SMEDDS
Preconcentrate Observation
F1 No sign of cloudiness/clear solution
F2 No sign of cloudiness/clear solution
F3 No sign of cloudiness/clear solution
F4 No sign of cloudiness/clear solution
F5 No sign of cloudiness/clear solution
F6 No sign of cloudiness/clear solution
F7 No sign of cloudiness/clear solution
F8 No sign of cloudiness/clear solution
F9 No sign of cloudiness/clear solution
F10 No sign of cloudiness/clear solution
F11 No sign of cloudiness/clear solution
F12 No sign of cloudiness/clear solution
F13 No sign of cloudiness/clear solution
SMEDDS: Self-microemulsifying drug delivery system
Table 8: Results of the optical clarity test of bambuterol SMEDDS
Preconcentrate Percentage transmission
0 h 12 h 24 h
F1 97±0.7211 98±0.2 97.4±0.529
F2 97±0.7211 97.3±0.557 97.1±0.557
F3 97.1±0.625 97.6±0.4 97.4±0.529
F4 96.5±0.5 96.6±0.4 96.3±0.529
F5 96.3±0.458 96.3±0.608 95.7±0.721
F6 95.6±0.360 95.7±0.4 95.7±0.3
F7 99±0.265 98.3±0.4 97.4±0.3
F8 99±0.360 98.1±0.4 97±0.556
F9 99±0.2 98.3±0.3 97.7±0.4
F10 98.2±0.265 98.7±0.173 98.5±0.265
F11 99.3±0.173 99±0.173 98.4±0.173
F12 97.5±0.360 96.2±0.360 95.4±0.265
F13 97.3±0.360 96.1±0.360 95.7±0.265
Mean of three measurements±SD (n=3), 
SMEDDS: Self-microemulsifying drug delivery system

















Mean of three measurements±SD (n=3). 
SMEDDS: Self-microemulsifying drug delivery system
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viscosity of the SMEDDS. The viscosity measurements were done in 
triplicate.
Drug content
Irrespective of the concentration of oil, surfactant, and cosurfactant, 
the drug content in the 13 formulations was found to be in the range 
of 94.37–102.49% (p<0.05, t-test), indicating uniform dispersion of the 
drug in the SMEDDS (Table 11). The drug content of the samples was 
determined in triplicate.
Stability studies
The physical stability of a lipid-based formulation is also crucial to its 
performance, which can be adversely affected by precipitation of the 
drug in the excipient matrix. Physical instability can lead to phase 
separation of the excipient and active ingredients, affecting not only 
formulation performance but also visual appearance as well.
Preconcentrate containing 10 mg of the drug, bambuterol 
hydrochloride, was diluted with distilled water to form 5 g formulation. 
Correspondingly, preconcentrate without drug was also diluted with 
distilled water to form 5 g formulation and stored at room temperature 
and conditions and studied for 6 months. The dilution was done as per 
the ratios of all the three components (oil, Smix, and water) (Table 1) 
obtained from the phase diagram. Results tabulated in Table 12 show 
that there was no phase separation, precipitation of the drug, or any 
other excipients.
Likewise, preconcentrate loaded with drug and preconcentrate without 
drug were stored at room temperature for 6 months. Results tabulated 
in Table 13 shows that there was no phase separation, precipitation of 
the drug, or any other excipients. Thus, it can be concluded that both the 
SMEDDS and microemulsions are stable under room conditions.
Thermodynamic stability studies
Heating and cooling cycle/stability testing: All the 13 formulations 
(preconcentrate containing 10 mg of the drug, bambuterol 
hydrochloride, diluted with distilled water to form 5 g formulation) did 
not show any sign of drug precipitation, phase separation, or turbidity 
when subjected to six cycles of heating and cooling. These formulations 
were then subjected to centrifuge test.
Centrifuge test
All the formulations, [F1-F13], were found to stable and passed the 
centrifuge test as phase separation was not observed. Results are 
tabulated in Table 14.
Comparative ex vivo intestinal permeability studies
Diffusion profile of SMEDDS F1 and F10 was compared with the diffusion 
profile of drug dissolved in distilled water. After 2 h, 16.17±0.26% of the 
drug diffused from the SMEDDS F1 and 12.06±0.26% of the drug diffused 
from SMEDDS F10, whereas from the plain drug solution, the diffusion 
was found to be 10.02±0.35% (p<0.05, t-test). After 2 h, the amount of 
drug diffusing out of SMEDDS F1 was 1.6 times more as compared to plain 
bambuterol solution, whereas the amount of drug diffusing out of SMEDDS 
F10 was 1.2 times more as compared to bambuterol solution. The drug 
diffused at a faster rate from SMEDDS F1 as compared to SMEDDS F10 and 
plain drug (Table 15 and Fig. 11) due to increased permeability of the drug 
across the intestine. This may be attributed to the fact that the presence 
of alcohol affects the physical properties of water. Ethanol disrupts the 
water structure, creating an increase in the lipophilic character of Tween 
Table 10: Viscosity of various bambuterol SMEDDS
Preconcentrate Viscosity (cp)
2 rpm 6 rpm 12 rpm
F1 928±17.44 330±3.6 208±3.46
F2 903±6.08 325±4.58 196±2.65
F3 940±10.15 350±2.65 188±7.00
F4 900±8.54 337±2.0 208±6.08
F5 1018±14.73 363±4.58 208±3.0
F6 1000±4.58 378±6.56 210±1.0
F7 888±8.0 330±4.58 179±3.60
F8 895±5.57 330±5.0 189±2.0
F9 967±7.0 346±3.60 194±2.64
F10 1050±9.0 401±3.60 251±4.58
F11 1060±9.64 401±7.0 237±2.0
F12 1121±10.26 457±8.0 296±5.57
F13 1110±12.52 433±6.25 300±3.0
Mean of three measurements±SD (n=3), 
SMEDDS: Self-microemulsifying drug delivery system
Table 11: Drug content of 13 SMEDDS formulations of 
bambuterol














Mean of three measurements±SD (n=3), 
SMEDDS: Self-microemulsifying drug delivery system
Table 12: Result of stability studies of bambuterol microemulsion at room temperature
Formulation Formulation without drug Formulation with drug
3 months 6 months 3 months 6 months
F1 No phase separation No phase separation No phase separation No phase separation
F2 No phase separation No phase separation No phase separation No phase separation
F3 No phase separation No phase separation No phase separation No phase separation
F4 No phase separation No phase separation No phase separation No phase separation
F5 No phase separation No phase separation No phase separation No phase separation
F6 No phase separation No phase separation No phase separation No phase separation
F7 No phase separation No phase separation No phase separation No phase separation
F8 No phase separation No phase separation No phase separation No phase separation
F9 No phase separation No phase separation No phase separation No phase separation
F10 No phase separation No phase separation No phase separation No phase separation
F11 No phase separation No phase separation No phase separation No phase separation
F12 No phase separation No phase separation No phase separation No phase separation
F13 No phase separation No phase separation No phase separation No phase separation
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80 [33,34]. Further ethanol provokes a decrease in mixture viscosity [35]; 
therefore, Tween 80 can reach the interface faster.
CONCLUSION
In this study, SMEDDS of a drug having poor bioavailability, bambuterol 
hydrochloride was formulated successfully by ultrasonication method 
for oral administration. Components of the SMEDDS formulation and 
their ratios were obtained by solubility studies and pseudo ternary 
phase diagram. The SMEDDS formulations were assessed for globule 
size, emulsification time, zeta potential, robustness on dilution, light 
transmission, viscosity, drug content and loading, stability, and ex vivo 
permeability.
The formulation F1 containing 10 mg bambuterol hydrochloride, 
triacetin (12.50% w/w), Tween 80 (43.75% w/w), and ethanol 
(43.75% w/w) was concluded to be optimum. The optimized SMEDDS 
not only showed optimum globule size, zeta potential, and drug 
content but was also found to be robust to dilution, forms emulsion 
spontaneously, and was stable. The optimized SMEDDS showed 
increased permeability of the drug across the intestinal membrane 
when compared with plain drug solution and formulation F10, in 
ex vivo studies.
The results suggest that bambuterol hydrochloride can be formulated 
as self-microemulsifying drug delivery system and further SMEDDS can 
be used to improve the oral bioavailability of bambuterol hydrochloride.
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